文献速递膀胱癌与上尿路尿路上皮癌

阿替利珠单抗治疗铂类治疗后局部晚期或转移性尿路上皮癌:按既往方案数的结局

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
PubMed 文献 · Eur Urol · 2017-12-20

IMvigor210是一项2期单臂两队列研究,纳入315例铂类治疗后进展的mUC患者,接受阿替利珠单抗1200mg每3周静脉给药。

要点

  • 阿替利珠单抗1200mg每3周静脉给药用于铂类治疗后mUC。
  • 初治亚组ORR 25%(95%CI 14-38),中位OS 9.6个月(95%CI 5.9-15.8)。
  • 各治疗线数间疗效与毒性无显著差异。

核心结论

  • 阿替利珠单抗在铂类治疗后mUC患者中,各治疗线数间显示可比的有效性和安全性。

研究设计与样本

  • 关键入选标准包括年龄≥18岁、肌酐清除率≥30ml/min、ECOG体能状态0-1,既往治疗线数不限。
  • 本队列患者接受阿替利珠单抗1200mg静脉给药每3周一次,直至临床获益丧失。

主要发现

  • 所有预设亚组均出现客观缓解和OS延长,大多数亚组中位缓解持续时间未达到。
  • 无既往系统性mUC治疗(一线亚组)患者ORR为25%(95%CI 14-38),中位OS为9.6个月(95%CI 5.9-15.8)。
  • 未观察到疗效或毒性随治疗线数出现显著差异。

关键数值与推荐

  • 客观缓解率(ORR)采用中心评估的RECIST v1.1标准。
  • 亚组间差异采用log-rank检验(OS)和卡方检验(ORR及不良事件频率)。

临床怎么用

  • 阿替利珠单抗1200mg每3周静脉给药可用于铂类治疗后进展的mUC患者,既往治疗线数不影响疗效或毒性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with metastatic urothelial carcinoma (mUC) who progress after platinum-based chemotherapy have had few treatment options and uniformly poor outcomes. Atezolizumab (anti-programmed death-ligand 1) was approved in the USA for cisplatin-ineligible and platinum-treated mUC based on IMvigor210, a phase 2, single-arm, two-cohort study. OBJECTIVE: To evaluate the efficacy and safety of atezolizumab by the number of prior lines of systemic therapy in patients with pretreated mUC. DESIGN, SETTING, AND PARTICIPANTS: IMvigor210 enrolled 315 patients with mUC with progression during or following platinum-based therapy at 70 international sites between May 2014 and November 2014. Key inclusion criteria included age ≥18 yr, creatinine clearance ≥30ml/min, and Eastern Cooperative Oncology Group performance status 0-1, with no limit on prior lines of treatment. INTERVENTION: Patients in this cohort received atezolizumab 1200mg intravenously every 3 wk until loss of clinical benefit. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Centrally assessed Response Evaluation Criteria In Solid Tumors v1.1 objective response rate (ORR), median duration of response, overall survival (OS), and adverse events were evaluated by prior treatment. Potential differences between subgroups were evaluated using log-rank (for OS) and chi-square (for ORR and adverse events frequencies) testing. RESULTS AND LIMITATIONS: Three hundred and ten patients were efficacy and safety evaluable (median follow-up, 21 mo). Objective responses and prolonged OS occurred across all prespecified subgroups; median duration of response was not reached in most subgroups. In patients without prior systemic mUC therapy (first-line subgroup), ORR was 25% (95% confidence interval: 14-38), and median OS was 9.6 mo (95% confidence interval: 5.9-15.8). No significant differences in efficacy or toxicity by therapy line were observed. CONCLUSIONS: Atezolizumab demonstrated comparable efficacy and safety in previously treated patients with mUC across all lines of therapy evaluated. PATIENT SUMMARY: We investigated effects of previous treatment in patients with metastatic urothelial carcinoma that progressed after platinum-based therapy. Atezolizumab was active and tolerable no matter how many treatment regimens patients had received. ClinicalTrials.gov, NCT02108652.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Perez-Gracia JL, Loriot Y, Rosenberg JE, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol. 2017. PMID: 29273410. doi:10.1016/j.eururo.2017.11.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。